ADRs came under pressure in the premarket on Thursday after the company announced its decision to halt a clinical program ...

BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study. BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab ...

Precious metals are not merely ornaments; they are also important components of pharmaceuticals, like the antitumor drug ...

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

This week Bobbi Conner talks with Dr. Miriam Alexander about advances in lung cancer treatment in recent years. Dr. Alexander ...

TIGIT in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Feb. 12, 2025 — Researchers have found that some particularly aggressive lung cancer cells can develop their own electric network, like that seen in the body's nervous ... Feb. 6, 2025 ...

The battle against drug resistance in lung cancer therapy remains a critical issue in oncology, with resistance mechanisms ...